2-hydroxyethyl terephthalic acid diester hydrolase mutant, coding gene, recombinant vector, recombinant strain, enzyme preparation and application

By mutation of specific amino acid sites of 2-hydroxyethyl terephthalate diester hydrolase, a mutant enzyme that can stably degrade BHET into MHET under different pH conditions was designed, and the directionality in the prior art was solved The problem of low performance and product mixing achieves efficient catalytic efficiency and thermal stability, and has broad industrial application prospects.

CN118910001APending Publication Date: 2024-11-08NANJING NORMAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411294382.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing 2-hydroxyethyl terephthalate hydrolase has low orientation and product mixing is not conducive to subsequent applications. It cannot effectively degrade BHET into a single product MHET, and its activity is limited by pH conditions.

Method used

A high product selection was designed by performing specific mutations in the amino acid sequence of wild-type 2-hydroxyethyl terephthalate hydrolase from Bacillus subtilis origin, especially mutations at sites 185, 306 and 359. mutant enzymes can stably degrade BHET into MHET under different pH conditions, avoiding further degradation to TPA.

Benefits of technology

The 100% directional degradation of BHET to MHET is achieved, which improves catalytic efficiency and product selectivity. The enzymatic lysis process is not limited by pH conditions and has high thermal stability. It is suitable for industrial applications of plastics and their intermediates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910001A_ABST
    Figure CN118910001A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of enzyme engineering and biology, and discloses a 2-hydroxyethyl terephthalic acid diester hydrolase mutant, a coding gene, a recombinant vector, a recombinant strain, an enzyme preparation and application. The 2-hydroxyethyl terephthalic acid diester hydrolase mutant is obtained by mutating at least one of the 105 site, the 106 site, the 185 site, the 187 site, the 188 site, the 191 site, the 192 site, the 193 site, the 214 site, the 215 site, the 216 site, the 306 site, the 307 site, the 311 site, the 359 site and the 398 site of an amino acid sequence shown in SEQ ID NO.2. The mutant can directionally convert BHET into MHET and cannot be further hydrolyzed into a hydrolase mutant of TPA, and directional conversion of the MHET is achieved through the reaction. The 2-hydroxyethyl terephthalic acid diester hydrolase mutant is not controlled by the pH condition, and has excellent thermal stability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of enzyme engineering and biotechnology, and in particular to a 2-hydroxyethyl terephthalate diester hydrolase mutant and a coding gene thereof, a recombinant vector, a recombinant strain, an enzyme preparation and applications thereof in degrading plastics and intermediates thereof. Background Art

[0002] Since its introduction, synthetic plastics have been widely used in many aspects of human life due to their plasticity and stability. At present, synthetic plastics mainly include two categories: polyesters (polyethylene terephthalate PET, polyurethane PUR) and polyolefins (polyethylene PE, polypropylene PP, polystyrene PS, polyvinyl chloride PVC). Since synthetic plastics are high-molecular compounds formed by monomer addition or polycondensation reactions, they have the characteristics of high crystallinity, strong hydrophobicity, and stable physical and chemical properties. Therefore, synthetic plastics have very strong resistance to degradation. Waste plastics decompose slowly in the natural environment, resulting in a large amount of plastic waste accumulating in the land and ocean, causing global "white" pollution.

[0003] As the fourth largest polymer in the world, the degradation of polyethylene terephthalate (PET) and its intermediates has always attracted much attention. At present, the research on the degradation of PET is mainly focused on the efficient depolymerization of PET, while there are few studies on PET intermediates such as bis-2-hydroxyethyl terephthalate (BHET) and mono-2-hydroxyethyl terephthalate (MHET). Compared with traditional physical and chemical methods, enzymatic degradation of BHET has many advantages such as fewer reaction steps, less waste generation, environmental protection, lower production costs, fewer impurities in products, easy separation and excellent quality. Therefore, enzymatic degradation of petroleum-based plastics is one of the development trends of plastic degradation.

[0004] 2-Hydroxyethyl terephthalate hydrolase (BsEst, EC3.1.1.1) from Bacillus subtilis PET-86, also known as carboxylesterase, is an α / β hydrolase. The enzyme has good catalytic esterification / deesterification properties. In the enzymatic hydrolysis of 2-HET, the hydrolysis reaction is mainly carried out under kinetic control. There are mainly two reactions in the hydrolysis system: (1) BHET removes EG and hydrolyzes to MHET; (2) MHET further removes ethylene glycol (EG) and hydrolyzes to TPA. The final conversion rate depends on the balance between these two reactions.

[0005] Although the existing wild-type 2-hydroxyethyl terephthalate diester hydrolase can hydrolyze bis2hydroxyethyl terephthalate (BHET) into mono2hydroxyethyl terephthalate (MHET) and terephthalic acid (TPA), the mixed product is not conducive to subsequent applications. Therefore, it is necessary to modify the wild-type 2-hydroxyethyl terephthalate diester hydrolase to hydrolyze BHET into a single product. Summary of the invention

[0006] The purpose of the present invention is to overcome the problems of low directivity of 2-hydroxyethyl terephthalate diester hydrolase in the prior art and the mixed product (MHET and TPA) being unfavorable for subsequent application, and to provide a 2-hydroxyethyl terephthalate diester hydrolase mutant and its encoding gene, recombinant vector, recombinant strain and enzyme preparation and their application. The 2-hydroxyethyl terephthalate diester hydrolase mutant has high product selectivity, can directionally degrade BHET into MHET, and its activity is not limited by pH conditions, and has excellent thermal stability.

[0007] In order to achieve the above-mentioned object, the first aspect of the present invention provides a 2-hydroxyethyl terephthalate diester hydrolase mutant, wherein the 2-hydroxyethyl terephthalate diester hydrolase mutant is an enzyme having an amino acid sequence shown in SEQ ID NO.2, wherein at least one of positions 105, 106, 185, 187, 188, 191, 192, 193, 214, 215, 216, 306, 307, 311, 359 and 398 is mutated.

[0008] Preferably, the 2-hydroxyethyl terephthalate diester hydrolase mutant is an enzyme having an amino acid sequence as shown in SEQ ID NO.2 with at least one of the 185th, 306th and 359th positions mutated.

[0009] Preferably, the 2-hydroxyethyl terephthalate diester hydrolase mutant has mutation patterns of T306D, T306H, T306Q, T306D, T306H, T306Q, T359D, T359K, T359N and T359Q.

[0010] The second aspect of the present invention provides a gene encoding a 2-hydroxyethyl terephthalate diester hydrolase mutant, wherein the gene has a nucleotide sequence encoding the 2-hydroxyethyl terephthalate diester hydrolase mutant as described above.

[0011] The third aspect of the present invention provides a recombinant vector, which contains the gene as described above.

[0012] The fourth aspect of the present invention provides a recombinant strain, which contains the gene or the recombinant vector as described above.

[0013] A fifth aspect of the present invention provides a method for preparing a 2-hydroxyethyl terephthalate diester hydrolase mutant, the method comprising: inoculating the aforementioned recombinant strain into a fermentation medium for fermentation culture.

[0014] The sixth aspect of the present invention provides an enzyme preparation, which comprises the 2-hydroxyethyl terephthalate diester hydrolase mutant prepared by the method described above.

[0015] The seventh aspect of the present invention provides the use of at least one of the 2-hydroxyethyl terephthalate diester hydrolase mutant as described above, the gene as described above, the recombinant vector as described above, the recombinant strain as described above, the 2-hydroxyethyl terephthalate diester hydrolase mutant prepared by the method as described above, and the enzyme preparation as described above in the polyethylene terephthalate plastic intermediate BHET.

[0016] In an eighth aspect, the present invention provides a method for degrading a polyethylene terephthalate plastic intermediate BHET using at least one of the 2-hydroxyethyl terephthalate diester hydrolase mutant, the gene, the recombinant vector, the recombinant strain, the 2-hydroxyethyl terephthalate diester hydrolase mutant prepared by the method described above, and the enzyme preparation described above.

[0017] Through the above technical scheme, the present invention mutates the wild-type 2-hydroxyethyl terephthalate diester hydrolase derived from Bacillus subtilis PET-86 through rational design technology, and provides a variety of new 2-hydroxyethyl terephthalate diester hydrolase mutants, all of which can achieve 100% directional degradation of BHET to MHET without further degradation to the terminal product TPA, which not only improves the catalytic efficiency of the hydrolase, but also has extremely high product selectivity; the enzymatic hydrolysis process is not limited by pH conditions and has high thermal stability.

[0018] The 2-hydroxyethyl terephthalate diester hydrolase mutant provided by the invention has broad industrial application prospects in the degradation of plastics and their intermediates. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is a diagram showing the directional conversion effect of the mutant enzymes at three preferred sites in Example 1 on plastics and their intermediates;

[0020] Figure 2 It is the reaction principle diagram of Example 3;

[0021] Figure 3 This is the result of alanine scanning in Example 1;

[0022] Figure 4 The effect of different pH on the hydrolysis of BHET to produce MHET by 2-hydroxyethyl terephthalate diester hydrolase mutants;

[0023] Figure 5 The effect of different temperatures on the activity of 2-hydroxyethyl terephthalate diester hydrolase mutants. DETAILED DESCRIPTION

[0024] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0025] The first aspect of the present invention provides a 2-hydroxyethyl terephthalate diester hydrolase mutant, which is an enzyme having an amino acid sequence shown in SEQ ID NO.2, with at least one of the 105th, 106th, 185th, 187th, 188th, 191st, 192nd, 193rd, 214th, 215th, 216th, 306th, 307th, 311th, 359th and 398th positions being mutated.

[0026] During the research process, the inventors of the present invention used AI deep learning enzyme engineering technology to mutate the wild-type 2-hydroxyethyl terephthalate diester hydrolase (referred to as wild-type BsEst) from Bacillus subtilis PET-86, whose amino acid sequence is shown in SEQ ID NO.2, wherein, because a purification tag is added to the target protein, the sequence has ten more sites: alanine, alanine, leucine, glutamic acid, histidine, histidine, histidine, histidine, histidine and histidine (AALEHHHHH at the end of the SEQ ID NO.2 sequence), and the nucleotide sequence is shown in SEQ ID NO.1. Specifically, through the first step of the trigger engineering: tunnel analysis and surrounding residue statistics, 123 amino acid residues were obtained; through the second step of the trigger engineering: statistics of the catalytic residues around the active site, there were 22 amino acid residues, and the amino acid positions overlapping with the first step were selected, and there were 19 amino acid residue sites; through the third step of the trigger engineering: the amino acids at 19 positions were mutated to alanine, and there were 16 mutants as follows: G105A, G106A, V185A, G187A, E188A, G191A, G192A, M193A, E214A, S215A, G216A, T306A, T307A, G311A, T359A and F398A.

[0027] Through Figure 3 As shown in the alanine scanning result in Figure a, the three mutations V185A, T306A, and T359A can convert the substrate BHET 100%. Figure 3 As shown in Figure b of the alanine scanning result, the three mutants V185A, T306A, and T359A can generate more MHET instead of TPA compared with the wild-type BsEst while converting the substrate BHET 100%. Therefore, preferably, the 2-hydroxyethyl terephthalate diester hydrolase mutant is a mutated enzyme having an amino acid sequence shown in SEQ ID NO.2 at one of the 185th, 306th, and 359th positions.

[0028] The 185th, 306th and 359th sites were subjected to PCR site-directed saturation mutagenesis to obtain the mutant gene sequence, the mutant gene sequence was inserted into the PET-226b plasmid to obtain an expression vector, and transformed into Escherichia coli to obtain recombinant engineered bacteria for screening. The fermentation was induced with IPTG and purified by affinity chromatography to obtain the 2-hydroxyethyl terephthalate diester hydrolase mutant. Compared with the wild-type 2-hydroxyethyl terephthalate diester hydrolase, the mutant enzyme produced more MHET instead of TPA in the degradation of plastics and their intermediates. Therefore, the three sites 185, 306, and 359 can effectively trigger the product selectivity of BHET.

[0029] According to the present invention, preferably, the 2-hydroxyethyl terephthalate diester hydrolase mutant is an enzyme having an amino acid sequence as shown in SEQ ID NO.2 subjected to at least one of the mutations (1) to (3):

[0030] (1) The valine V at position 185 is mutated to alanine A, cysteine ​​C, aspartic acid D, glutamic acid E, phenylalanine F, glycine G, histidine H, isoleucine I, lysine K, leucine L, methionine M, asparagine N, proline P, glutamine Q, arginine R, serine S, threonine T, tryptophan W, and tyrosine Y, represented by V185A, V185C, V185D, V185E, V185F, V185G, V185H, V185I, V185K, V185L, V185M, V185N, V185P, V185Q, V185R, V185S, V185T, V185W, and V185Y, respectively.

[0031] (2) The threonine T at position 306 is mutated to alanine A, cysteine ​​C, aspartic acid D, glutamic acid E, phenylalanine F, glycine G, histidine H, isoleucine I, lysine K, leucine L, methionine M, asparagine N, proline P, glutamine Q, arginine R, serine S, valine V, tryptophan W, and tyrosine Y, represented by T306A, T306C, T306D, T306E, T306F, T306G, T306H, T306I, T306K, T306L, T306M, T306N, T306P, T306Q, T306R, T306S, T306V, T306W, and T306Y, respectively.

[0032] (3) The threonine T at position 359 is mutated to alanine A, cysteine ​​C, aspartic acid D, glutamic acid E, phenylalanine F, glycine G, histidine H, isoleucine I, lysine K, leucine L, methionine M, asparagine N, proline P, glutamine Q, arginine R, serine S, valine V, tryptophan W, and tyrosine Y, represented by T359A, T359C, T359D, T359E, T359F, T359G, T359H, T359I, T359K, T359L, T359M, T359N, T359P, T359Q, T359R, T359S, T359V, T359W, and T359Y, respectively.

[0033] Preferably, the 2-hydroxyethyl terephthalate diester hydrolase mutant has mutation patterns of T306D, T306H, T306Q, T306D, T306H, T306Q, T359D, T359K, T359N and T359Q.

[0034] The inventors found that under this preferred embodiment, BHET is advantageously degraded to MHET in a targeted manner, the catalytic efficiency is improved, and it is not controlled by pH conditions and has high thermal stability.

[0035] The above-mentioned 2-hydroxyethyl terephthalate diester hydrolase mutant can be obtained by artificial synthesis, or its coding gene can be synthesized first and then obtained by biological expression. Exemplarily, the 2-hydroxyethyl terephthalate diester hydrolase mutant provided in the present invention is mutated by using a site-directed saturation mutagenesis technique to mutate the coding gene of the amino acid sequence shown in SEQ ID NO.2, and the host Escherichia coli is transformed after connecting the expression vector, and the corresponding mutant protein is obtained after adding 0.1mM IPTG low-temperature induction for about 24h, and BHET is used as a substrate to perform a degradation catalytic reaction; Subsequently, the content of the substrate BHET and the product MHET and TPA is detected by high-performance liquid chromatography to obtain a 2-hydroxyethyl terephthalate diester hydrolase mutant, and the activity of catalyzing the directional hydrolysis of 2-hydroxyethyl terephthalate diester (BHET) to MHET is significantly improved.

[0036] The second aspect of the present invention provides a gene encoding a 2-hydroxyethyl terephthalate diester hydrolase mutant, wherein the gene has a nucleotide sequence encoding the 2-hydroxyethyl terephthalate diester hydrolase mutant as described above.

[0037] It is well known in the art that among the 20 different amino acids that make up proteins, except for Met (ATG) or Trp (TGG) which are encoded by a single codon, the other 18 amino acids are encoded by 2-6 codons respectively (Sambrook et al., Molecular Cloning, Cold Spring Harbor Laboratory Press, New York, USA, second edition, 1989, see Appendix D on page 950). That is, due to the degeneracy of the genetic code, there are usually more than one codon to determine an amino acid, and the substitution of the third nucleotide in the triplet codon often does not change the amino acid composition, so the nucleotide sequence of the gene encoding the same protein can be different.

[0038] The nucleotide sequences provided by the present invention can usually be obtained by polymerase chain reaction (PCR) amplification, recombination, or artificial synthesis. Once the relevant nucleotide sequence is obtained, the relevant amino acid sequence can be obtained in large quantities by recombination. The obtained nucleotide sequence is usually cloned into a vector, then transferred into genetically engineered bacteria, and then the relevant nucleotide sequence is isolated from the propagated host cells by conventional methods.

[0039] In addition, the relevant nucleotide sequences can also be synthesized by known artificial chemical synthesis methods.

[0040] The third aspect of the present invention provides a recombinant vector, which contains the gene as described above. In the present invention, the "vector" used in the recombinant vector can be selected from various vectors known in the art, such as various commercially available plasmids, cosmids, phages and retroviruses, etc. The preferred expression vector of the present invention is the PET-226b plasmid. Exemplarily, the expression vector and the target fragment are connected by seamless cloning to obtain a recombinant vector.

[0041] The fourth aspect of the present invention provides a recombinant strain, which contains the gene or the recombinant vector as described above.

[0042] In the present invention, the recombinant vector can be transformed, transduced or transfected into a host cell (strain) by conventional methods in the art, such as chemical transformation by calcium chloride method or high voltage electroporation transformation. The host cell can be a prokaryotic cell or a eukaryotic cell, preferably Escherichia coli or Bacillus subtilis, more preferably, the host cell is Escherichia coli, such as Escherichia coli BL21 (DE3).

[0043] A fifth aspect of the present invention provides a method for preparing a 2-hydroxyethyl terephthalate diester hydrolase mutant, the method comprising: inoculating the aforementioned recombinant strain into a fermentation medium for fermentation.

[0044] In the present invention, there is no particular restriction on the conditions for fermentation of the recombinant strain, as long as the recombinant strain can be proliferated in large quantities through the fermentation process. Preferably, the fermentation process comprises: firstly carrying out seed culture of the recombinant strain to obtain a seed solution, then inoculating the seed solution into a fermentation medium containing kanamycin and culturing it until the bacterial concentration OD600 is 0.5-0.7, then adding an isopropyl-β-D-thiogalactoside (IPTG) inducer with a final concentration of 0.1-0.2 mM, and culturing at a temperature of 10-20°C for 20-30 hours to obtain a fermentation liquid.

[0045] According to the present invention, preferably, the content of kanamycin in the fermentation medium is 40-60 mg / L.

[0046] Further preferably, the method for preparing the seed solution comprises: picking a single colony of the recombinant strain and inoculating it into a seed culture medium containing kanamycin for seed culture to obtain the seed solution. In the present invention, the single colony of the recombinant strain can be selected from the freshly prepared recombinant strain or the recombinant strain frozen at low temperature (for example, a recombinant strain of synthetic lipids frozen in a glycerol cryopreservation tube in a -80°C refrigerator).

[0047] The present invention has no particular restrictions on the method of seed culture, as long as the recombinant strain can be activated and proliferated by the method. Preferably, the content of kanamycin in the seed culture medium is 40-60 mg / L; the temperature, pH, rotation speed, time and other parameters used in seed culture can be conventional settings in the art. Preferably, the conditions of seed culture include: temperature of 30-45°C, rotation speed of 150-250rpm, and time of 8-12h.

[0048] In the present invention, there is no particular limitation on the seed culture medium and the fermentation culture medium, and they can be culture medium conventionally used in the art. Preferably, the seed culture medium and the fermentation culture medium are LB liquid culture medium (peptone 8-12 g / L, yeast powder 4-6 g / L, NaCl 8-12 g / L)

[0049] The sixth aspect of the present invention provides an enzyme preparation, which comprises the 2-hydroxyethyl terephthalate diester hydrolase mutant prepared by the method described above.

[0050] In the present invention, the 2-hydroxyethyl terephthalate diester hydrolase mutant can be made into a corresponding enzyme preparation. Specifically, the enzyme preparation can be in a solid, semi-solid or liquid form. The enzyme preparation can be separated by a conventional Ni+ column purification method in the art.

[0051] The 2-hydroxyethyl terephthalate diester hydrolase mutant provided by the present invention has high thermal stability, and the catalytic efficiency and directional catalytic effect on the degradation of PET plastic intermediate BHET are also significantly improved. The seventh aspect of the present invention provides the use of at least one of the 2-hydroxyethyl terephthalate diester hydrolase mutant as described above, the gene as described above, the recombinant vector as described above, the recombinant strain as described above, the 2-hydroxyethyl terephthalate diester hydrolase mutant prepared by the method as described above, and the enzyme preparation as described above in degrading plastics and their intermediates.

[0052] According to the present invention, the plastic and its intermediate are selected from 2-hydroxyethyl terephthalate (BHET), an intermediate product of polyethylene terephthalate (PET).

[0053] In the present invention, the method for degrading the PET intermediate BHET may include: contacting at least one of the aforementioned 2-hydroxyethyl terephthalate diester hydrolase mutant, the aforementioned gene, the aforementioned recombinant vector, the aforementioned recombinant strain, the 2-hydroxyethyl terephthalate diester hydrolase mutant prepared by the aforementioned method, and the aforementioned enzyme preparation with BHET; wherein the contact conditions include: a temperature of 30-50° C., a rotation speed of 800-1000 rpm, and a time of 4-8 h.

[0054] The 2-hydroxyethyl terephthalate diester hydrolase mutant has the ability to degrade the PET plastic intermediate BHET in a targeted manner, has high thermal stability, and is not controlled by pH conditions. The BsEst mutant will have great potential in degrading PET plastics and its intermediates, and has broad application prospects in biochemical engineering.

[0055] The present invention will be described in detail below through examples.

[0056] In the following examples, Escherichia coli BL21 (DE3) was purchased from Baoli Biotechnology (Dalian) Co., Ltd. with the serial number 9126; PET-226b plasmid was purchased from Sangon Biotechnology (Shanghai) Co., Ltd. with the serial number B540183; seamless cloning kit was purchased from Beyotime Biotechnology Co., Ltd., MHET standard was purchased from Sigma, BHET standard and TPA standard were purchased from MacLean Reagent Co., Ltd.; the remaining reagents and raw materials were conventional commercial products.

[0057] LB liquid medium: tryptone 10g / L, yeast extract 5g / L, NaCl 10g / L, pH adjusted to 6.5, steam sterilized under high pressure for 21min, and set aside;

[0058] LB agar plate medium: tryptone 10g / L, yeast extract 5g / L, NaCL 10g / L, agar 12g / L, pH adjusted to 7.0, steam sterilized under high pressure for 21min, and set aside;

[0059] Detection of BHET, TPA and MHET content: First, perform HPLC analysis with standard solutions of gradient concentrations to obtain a standard curve of chromatographic peak area and standard concentration; take 200 μL of sample supernatant and add it to 200 μL of methanol to terminate the reaction, filter it through a 0.22 μM filter membrane, and perform HPLC analysis;

[0060] HPLC test conditions are as follows: chromatographic column: C18 reverse phase column; column temperature: 30°C; detection wavelength: 240nm; flow rate: 0.7ml·min-1; injection volume: 10μl; mobile phase: 40% methanol (chromatographic grade), 60% water (one thousandth acetic acid).

[0061] Example 1

[0062] This example illustrates the site-directed mutagenesis of 2-hydroxyethyl terephthalate diester hydrolase

[0063] S1. The wild-type 2-hydroxyethyl terephthalate diester hydrolase (abbreviated as wild-type BsEst, amino acid sequence as shown in SEQ ID NO.1, nucleotide sequence as shown in SEQ ID NO.2) from Bacillus subtilis PET-86 was modified by AI deep learning enzyme engineering technology. NO.2) for mutation: specifically, through the first step of triggering engineering: tunnel analysis and surrounding residue statistics, 123 amino acid residues were obtained, through the second step of triggering engineering: statistics of catalytic residues around the active site, there were 22 amino acid residues, and the amino acid positions overlapping with the first step were selected, there were 19 amino acid residue sites, through the third step of triggering engineering: the amino acids at 19 positions were mutated to alanine respectively, and there were the following 16 mutants: G105A, G106A, V185A, G187A, E188A, G191A, G192A, M193A, E214A, S215A, G216A, T306A, T307A, G311A, T359A, and F398A.

[0064] According to the results of the alanine scan ( Figure 2 ), that is, the three mutants V185A, T306A, and T359A generate more MHET than the wild type while the substrate BHET is 100% converted; therefore, it is believed that the three sites 185, 306, and 359 can effectively trigger the product selectivity of BHET. Therefore, it is preferred to perform site-directed saturation mutagenesis on one or more of the 185th, 306th, and 359th sites;

[0065] (1) The valine V at position 185 is mutated to alanine A, cysteine ​​C, aspartic acid D, glutamic acid E, phenylalanine F, glycine G, histidine H, isoleucine I, lysine K, leucine L, methionine M, asparagine N, proline P, glutamine Q, arginine R, serine S, threonine T, tryptophan W, and tyrosine Y, represented by V185A, V185C, V185D, V185E, V185F, V185G, V185H, V185I, V185K, V185L, V185M, V185N, V185P, V185Q, V185R, V185S, V185T, V185W, and V185Y, respectively.

[0066] (2) The threonine T at position 306 is mutated to alanine A, cysteine ​​C, aspartic acid D, glutamic acid E, phenylalanine F, glycine G, histidine H, isoleucine I, lysine K, leucine L, methionine M, asparagine N, proline P, glutamine Q, arginine R, serine S, valine V, tryptophan W, and tyrosine Y, represented by T306A, T306C, T306D, T306E, T306F, T306G, T306H, T306I, T306K, T306L, T306M, T306N, T306P, T306Q, T306R, T306S, T306V, T306W, and T306Y, respectively.

[0067] (3) The threonine T at position 359 is mutated to alanine A, cysteine ​​C, aspartic acid D, glutamic acid E, phenylalanine F, glycine G, histidine H, isoleucine I, lysine K, leucine L, methionine M, asparagine N, proline P, glutamine Q, arginine R, serine S, valine V, tryptophan W, and tyrosine Y, represented by T359A, T359C, T359D, T359E, T359F, T359G, T359H, T359I, T359K, T359L, T359M, T359N, T359P, T359Q, T359R, T359S, T359V, T359W, and T359Y, respectively.

[0068] like Figure 1 As shown, the mutant enzymes at the three sites have a directional conversion effect on plastics and their intermediates. The 10 mutants, V185G, V185Q, V185Y, T306D, T306H, T306Q, T359D, T359K, T359N, and T359Q, can achieve 100% conversion of the substrate BHET into MHET without further hydrolysis into TPA.

[0069] S2. Use SnapGene software to design blunt-end primers (as shown in Table 1), use the coding gene sequence (shown in SEQ ID NO.1) of the wild-type 2-hydroxyethyl terephthalate diester hydrolase amino acid sequence (shown in SEQ ID NO.2) of Bacillus subtilis PET-86 as a template, and then perform PCR site-directed mutagenesis.

[0070] Table 1

[0071] Primer Name Primer Sequence (5' to 3') Number V185Q-F CCAATAACGTAACACAGTTTGGAGAATCCGCC SEQ ID NO.3 V185Q-R GGCGGATTCTCCAAACTGTGTTACGTTATTGG SEQ ID NO.4 V185Y-F CCAATAACGTAACATATTTTGGAGAATCCGCC SEQ ID NO.5 V185Y-R GGCGGATTCTCCAAAATATGTTACGTTATTGG SEQ ID NO.6 V185G-F CCAATAACGTAACAGGTTTTGGAGAATCCGCC SEQ ID NO.7 V185G-R GGCGGATTCTCCAAAACCTGTTACGTTATTGG SEQ ID NO.8 T306D-F GCATTCCGCTATTAATCGGAGATACCCGTGATGAAGG SEQ ID NO.9 T306D-R CCTTCATCACGGGTATCTCCGATTAATAGCGGAATGC SEQ ID NO.10 T306H-F GCATTCCGCTATTAATCGGACATACCCGTGATGAAGG SEQ ID NO.11 T306H-R CCTTCATCACGGGTATGTCCGATTAATAGCGGAATGC SEQ ID NO.12 T306Q-F GCATTCCGCTATTAATCGGACAGACCCGTGATGAAGG SEQ ID NO.13 T306Q-R CCTTCATCACGGGTCTGTCCGATTAATAGCGGAATGC SEQ ID NO.14 T359D-F GCCAAATTCATATGATGGATGATTTATTATTTTGGCGCCCTGC SEQ ID NO.15 T359D-R GCAGGGCGCCAAAATAATAAATCATCCATCATATGAATTTGGC SEQ ID NO.16 T359K-F GCCAAATTCATATGATGAAAGATTTATTATTTTGGCGCCCTGC SEQ ID NO.17 T359K-R GCAGGGCGCCAAAATAATAAATCTTTCATCATATGAATTTGGC SEQ ID NO.18 T359N-F GCCAAATTCATATGATGAATGATTTATTATTTTGGCGCCCTGC SEQ ID NO.19 T359N-R GCAGGGCGCCAAAATAATAAATCATTCATCATATGAATTTGGC SEQ ID NO.20 T359Q-R GCCAAATTCATATGATGCAGGATTTATTATTTTGGCGCCCTGC SEQ ID NO.21 T359Q-F GCAGGGCGCCAAAATAATAAATCCTGCATCATATGAATTTGGC SEQ ID NO.22

[0072] The PCR reaction system was as follows: PrimeSTAR Mix high-fidelity enzyme 25 μL, primer-1 (10 pmol / μL) 2 μL, primer-2 (10 pmol / μL) 2 μL, template 2 μL, ddH2O 19 μL;

[0073] PCR cycle process: 1. Preheating: 95℃, 10min; 2. Denaturation: 95℃, 30s; 3. Annealing: 60℃, 30s; 4. Extension: 72℃, 4min; 2-4 cycles 25 times; 5. Extension: 72℃, 10min; Cool to 4℃ for storage.

[0074] The PCR product was recovered and tested by agarose gel electrophoresis to determine whether the site-directed mutation was completed. Then, DpnI (1 μL) was added to the 50 μL system, kept at 37°C for 3 hours to digest the template, and cooled to 4°C for storage.

[0075] The mutated plasmids were transformed into competent Escherichia coli BL21 (DE3) cells, and positive recombinants were screened on a resistance plate containing ampicillin, and single clones were selected. The positive clones were verified by colony PCR and DNA sequencing to obtain the corresponding mutants (mutant V185G, mutant V185Q, mutant V185Y, mutant T306D, mutant T306H, mutant T306Q, mutant T359D, mutant T359K, mutant T359N, mutant T359Q).

[0076] Example 2

[0077] This example illustrates the induced expression and purification of a 2-hydroxyethyl terephthalate diester hydrolase mutant.

[0078] 1. Inducible expression of 2-hydroxyethyl terephthalate diester hydrolase mutant

[0079] (1) The recombinant transformant obtained in Example 1 was inoculated into LB medium (peptone 10 g / L, yeast powder 5 g / L, NaCl 10 g / L, pH 6.5) containing ampicillin and cultured at 37° C. with shaking for 12 h to obtain a seed solution.

[0080] (2) Inoculate 2% (v / v) of the inoculum into a 250 mL Erlenmeyer flask containing 100 mL of LB medium and culture in a shaking incubator at 37°C and 180 rpm. 600 When it reached 0.6, IPTG with a final concentration of 0.1 mmol / L was added as an inducer and induced at 16°C for 24 h.

[0081] (3) The culture medium was centrifuged, the cells were collected, and washed twice with physiological saline to obtain resting cells. The resting cells were suspended in 20 mL of pH 8.0 phosphate buffer, ultrasonically disrupted in an ice bath, and the supernatant was collected by centrifugation to obtain the crude enzyme solution.

[0082] 2. Purification of 2-Hydroxyethylterephthalate Diester Hydrolase Mutants

[0083] The protein was purified by Ni+ column purification: the collected wild-type and mutant crude enzyme solutions were filtered and added to Nisepharose 6 Fast Flow (FF) filler, and impurities were eluted with 10 column volumes of buffer A (10mM Tris-HCl pH 7.0, 250mMNaCl, 20mM imidazole), and then the target protein was eluted with buffer B (10mM Tris-HCl pH 7.0, 250mM NaCl, 250mM imidazole), and the collected target protein was subjected to SDS-PAGE protein electrophoresis.

[0084] Example 3

[0085] This experiment illustrates the application of 2-hydroxyethyl terephthalate diester hydrolase mutant in the hydrolysis of BHET.

[0086] The technical solution adopted in this embodiment is as follows Figure 2 shown.

[0087] Depend on Figure 2 As shown in the reaction formula, the 2-hydroxyethyl terephthalate diester hydrolase mutant can break one side ester bond of BHET and remove EG to generate the intermediate product MHET; but will not further break one side ester bond of MHET to generate the terminal product TPA.

[0088] Reaction system: pH 7.5 phosphate buffer was used as the reaction medium; the total reaction volume was 2 mL, containing 5 mM BHETS, 2-hydroxyethyl terephthalate diester hydrolase mutant enzyme solution (prepared in Example 2) was added, the reaction temperature was 30°C, the rotation speed was 900 rpm, the reaction was carried out for 6 h, and sampling was performed at regular intervals; the sample was diluted 10 times with a solvent (water: methanol: acetic acid = 60: 35: 5 (V / V)) and detected by HPLC.

[0089] The results showed that the 10 2-hydroxyethyl terephthalate diester hydrolase mutants prepared in Example 2 all had the ability to hydrolyze. The mutants directedly hydrolyzed BHET to MHET, with very little traditional end product TPA, and had broad application prospects in biochemical engineering.

[0090] Example 4

[0091] This experiment illustrates the effect of pH on the enzymatic hydrolysis of PET plastic intermediates.

[0092] Reaction system: pH 7.5 phosphate buffer was used as the reaction medium, the total reaction volume was 2 mL, 5 mM BHETS was contained therein, 2-hydroxyethyl terephthalate diester hydrolase mutant enzyme solution (prepared in Example 2) was added, the reaction was carried out for 6 h at a reaction pH of 5, 7, and 9 and a rotation speed of 900 rpm, and samples were taken at regular intervals. The sample was diluted 10 times with a solvent (water: methanol: acetic acid = 60: 35: 5 (V / V)), and HPLC was used for detection, and the results are shown in Table 2.

[0093] Table 2

[0094]

[0095] The results in Table 2 show that the 10 2-hydroxyethyl terephthalate diester hydrolase mutants prepared in Example 2 have the ability to hydrolyze. The mutants will hydrolyze BHET to MHET in a directional manner and are not controlled by pH conditions. The catalytic performance under different pH conditions fluctuates slightly, and has broad application prospects in biochemical engineering.

[0096] Example 5

[0097] This experiment illustrates the residual activity of mutants at different temperatures.

[0098] Reaction system: 2-hydroxyethyl terephthalate diester hydrolase mutant enzyme solution (prepared in Example 2) was incubated for 2 hours at reaction temperatures of 30°C, 40°C, 50°C, 60°C, and 70°C, followed by a pH 7.5 phosphate buffer as the reaction medium. The total reaction volume was 2 mL, which contained 5 mM BHET, and the incubated 2-hydroxyethyl terephthalate diester hydrolase mutant enzyme was added, and the reaction was carried out for 6 hours at a reaction temperature of 30°C and a rotation speed of 900 rpm, and samples were taken at regular intervals. The sample was diluted 10 times with a solvent (water: methanol: acetic acid = 60: 35: 5 (V / V)) and detected by HPLC. The results are shown in Table 3.

[0099] Table 3

[0100]

[0101] The results in Table 3 show that the 10 2-hydroxyethyl terephthalate diester hydrolase mutants prepared in Example 2 have high thermal stability at 30-50° C. and have broad application prospects in biochemical engineering.

[0102] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.

Claims

1. A 2-hydroxyethyl terephthalate diester hydrolase mutant, It is characterized in that The 2-hydroxyethyl terephthalate diester hydrolase mutant is prepared by mutating at least one of the 105th, 106th, 185th, 187th, 188th, 191st, 192nd, 193rd, 214th, 215th, 216th, 306th, 307th, 311th, 359th and 398th positions of the enzyme having the amino acid sequence shown in SEQ ID NO.

2.

2. The 2-hydroxyethyl terephthalate diester hydrolase mutant according to claim 1, It is characterized in that The 2-hydroxyethyl terephthalate diester hydrolase mutant is obtained by mutating at least one of the 185th, 306th and 359th positions of the enzyme having the amino acid sequence shown in SEQ ID NO.

2.

3. The 2-hydroxyethyl terephthalate diester hydrolase mutant according to claim 2, It is characterized in that The 2-hydroxyethyl terephthalate diester hydrolase mutant is obtained by subjecting the enzyme having the amino acid sequence shown in SEQ ID NO.2 to at least one of the mutations (1) to (3): (1) The valine V at position 185 is mutated to alanine A, cysteine ​​C, aspartic acid D, glutamic acid E, phenylalanine F, glycine G, histidine H, isoleucine I, lysine K, leucine L, methionine M, asparagine N, proline P, glutamine Q, arginine R, serine S, threonine T, tryptophan W, tyrosine Y, represented by V185A, V185C, V185D, V185E, V185F, V185G, V185H, V185I, V185K, V185L, V185M, V185N, V185P, V185Q, V185R, V185S, V185T, V185W, V185Y, respectively, preferably V185G, V185Q or V185Y. (2) The threonine T at position 306 is mutated to alanine A, cysteine ​​C, aspartic acid D, glutamic acid E, phenylalanine F, glycine G, histidine H, isoleucine I, lysine K, leucine L, methionine M, asparagine N, proline P, glutamine Q, arginine R, serine S, valine V, tryptophan W, and tyrosine Y, represented by T306A, T306C, T306D, T306E, T306F, T306G, T306H, T306I, T306K, T306L, T306M, T306N, T306P, T306Q, T306R, T306S, T306V, T306W, and T306Y, respectively, preferably T306D, T306H, and T306Q. (3) The threonine T at position 359 is mutated to alanine A, cysteine ​​C, aspartic acid D, glutamic acid E, phenylalanine F, glycine G, histidine H, isoleucine I, lysine K, leucine L, methionine M, asparagine N, proline P, glutamine Q, arginine R, serine S, valine V, tryptophan W, tyrosine Y, represented by T359A, T359C, T359D, T359E, T359F, T359G, T359H, T359I, T359K, T359L, T359M, T359N, T359P, T359Q, T359R, T359S, T359V, T359W, and T359Y, respectively, preferably T359D, T359K, T359N, and T359Q.

4. A gene encoding a mutant of 2-hydroxyethyl terephthalate diester hydrolase, It is characterized in that The gene has a nucleotide sequence encoding the 2-hydroxyethyl terephthalate diester hydrolase mutant according to any one of claims 1 to 3.

5. A recombinant vector, It is characterized in that The recombinant vector contains the gene according to claim 4; Preferably, the expression vector of the recombinant vector is pET-226b plasmid.

6. A recombinant strain, It is characterized in that The recombinant strain contains the gene according to claim 4 or the recombinant vector according to claim 5.

7. A method for preparing a mutant of 2-hydroxyethyl terephthalate diester hydrolase, It is characterized in that The preparation method comprises: inoculating the recombinant strain according to claim 6 into a fermentation medium for fermentation culture.

8. An enzyme preparation, It is characterized in that The enzyme preparation comprises the 2-hydroxyethyl terephthalate diester hydrolase mutant prepared by the method according to claim 7.

9. Use of at least one of the 2-hydroxyethyl terephthalate diester hydrolase mutant described in any one of claims 1 to 3, the gene described in claim 4, the recombinant vector and transformant described in claim 5, the recombinant strain described in claim 6, the 2-hydroxyethyl terephthalate diester hydrolase mutant prepared and purified by the method described in claim 7, and the enzyme preparation described in claim 8 in degrading plastics and their intermediates; preferably, in degrading BHET to MHET.

10. A method for degrading BHET, It is characterized in that The method comprises contacting at least one of the 2-hydroxyethyl terephthalate diester hydrolase mutant according to any one of claims 1 to 3, the gene according to claim 4, the recombinant vector and transformant according to claim 5, the recombinant strain according to claim 6, the 2-hydroxyethyl terephthalate diester hydrolase mutant prepared and purified by the method according to claim 7, and the enzyme preparation according to claim 8 with BHET; Preferably, the contacting conditions include: a temperature of 30-50°C.